Boron-Dipyrrin Complex for Selective Amyloid Oxidation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing flavin photocatalyst used for oxidizing Aβ peptides has nonspecific oxidative activity in vivo, making it difficult to apply in vivo and is limited to only Aβ peptides, while being ineffective on other amyloid-related diseases.
Innovation Solution
A boron-dipyrrin complex with a halogen atom or halogenoalkyl group is developed, which selectively oxidizes amyloid peptides, including toxic Aβ aggregates, with minimal activity on non-amyloid peptides, and is stable in water and under light irradiation, serving as both a catalyst and fluorescent dye.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a flavin photocatalyst is used to oxidize Aβ peptides, then oxidative activity against Aβ is achieved, but nonspecific oxidation occurs in vivo and selectivity is lost
Solution Approach 1:
The boron-dipyrrin complex is designed with specific molecular characteristics that enable it to selectively interact with amyloid structures. The complex exhibits localized oxidative activity only when bound to amyloid fibrils, maintaining high reliability against Aβ while avoiding nonspecific oxidation of other biomolecules in vivo.
Solution Approach 2:
The patent modifies the photocatalyst parameters by replacing flavin with a boron-dipyrrin complex structure. This structural parameter change fundamentally alters the selectivity profile, enabling the catalyst to distinguish between amyloid targets and other biological molecules, thereby eliminating nonspecific oxidation while preserving oxidative activity against Aβ.
2Reliability
If a flavin photocatalyst is used, then Aβ oxidation is achieved, but the catalyst is limited to only Aβ peptides and cannot treat other amyloid diseases
Solution Approach 1:
The boron-dipyrrin complex possesses universal binding characteristics that allow it to recognize and bind to various amyloid structures beyond just Aβ peptides. This structural universality enables a single catalyst to treat multiple amyloid diseases including Alzheimer's, Parkinson's, and other protein aggregation disorders, significantly expanding therapeutic applicability.
3Reliability
If the boron-dipyrrin complex is designed for high selectivity and stability, then in vivo applicability is achieved, but complex synthesis and optimization become more challenging
Solution Approach 1:
The boron-dipyrrin complex represents a composite material design that integrates boron coordination chemistry with dipyrrin macrocycle structure. This composite approach allows systematic optimization of selectivity and stability through modular structural modifications, balancing performance requirements with synthetic feasibility by building upon established chemical frameworks.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The boron-dipyrrin complex effectively oxygenates pathogenic amyloids, inhibiting their aggregation and is highly selective and stable, making it suitable for in vivo use as a therapeutic agent for amyloid-related diseases.
Implementation Method 1
a boron-dipyrrin complex, which is represented by the following formula (1), having a halogen atom or a halogenoalkyl group on the boron atom exhibits strong oxygenation activity on an Aβ peptide and other amyloids
Implementation Method 2
the boron-dipyrrin complex represented by the following formula (1) is useful as an in vivo catalyst which yields oxidized forms of amyloids having no aggregability
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided are a compound which is useful as an in vivo applicable, amyloid-oxygenating catalyst selective for amyloid and applicable not only to an Aβ peptide, but also to other amyloids and a drug containing the compound for preventing and/or treating amyloid-related diseases. Disclosed is a boron-dipyrrin complex represented by the following formula (1) wherein X1 and X2 are the same or different and each represent a halogenoalkyl group or a halogen atom; R1 represents a hydrogen atom, an alkyl group, or a group represented by formula (b): R2 and R6 are the same or different and each represent a hydrogen atom or a halogen atom; R3, R4, R5, and R7 are the same or different and each represent a hydrogen atom, a halogen atom, or an alkyl group; R8 represents a hydrogen atom or -(CH2)l-(Y)m-(CH2)n-Z wherein Y represents -CO-, -CONH-, or a triazole ring, Z represents a carboxyl group, a sulfonic acid group, or a -CO-peptide residue, 1 and n each represent an integer of 1 to 6, and m represents 0 or 1; R9 and R10 are the same or different and each represent a hydrogen atom, an alkyl group, an alkoxy group, a halogen atom, an amino group, a nitro group, or a cyano group; and R8 and R10 together optionally form an alkylene group.